chronic hepatitis C
Conditions
Interventions
Pegintron/rebetol
Pegintron/rebetol with celecoxib
Pegasys/copegas
Pegasys/copegas with celecoxib
Sponsors
Tokai University School of Medicine, Department of Internal Medicine, Division of Gastroenterology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients infected with genotype 1 2. Patients with serum HCV-RNA level of 5 LogIU/mL or more. 3. Neutrophil count >= 1500/mm3 4. Platelet count >= 100000/mm3 5. Hemoglobin concentration >= 12 g/dl
Exclusion criteria
Exclusion criteria: 1. Patients who were previously treated with pegylated interferon and ribavirin therapy. 2. Patients who are pregnant or lactating. 3. Patients who cannot use birth control until 6 months pass after the end of treatment. 4. Patients who have hypersensitivity to interferons or ribavirin. 5. Patients who have uncontrolled heart diseases. 6. Patients with abnormal hemoglobin diseases. 7. Patients with chronic renal failure. 8. Patients with severe depression. 9. Patients with severe liver diseases. 10. Patients with autoimmune disorders. 11. Patients receiving other antiviral drugs, immunomodulating drugs, or Sho-Sai-Ko-To. 12. Patients who have hypersensitivity to aspirin or NSAID. 13. Patients who have peptic ulcers. 14. Patients who have asthma induced by aspirin or NSAID. 15. Patients who received antiviral therapy within 6 months. 16. Patients who have a history of interstitial pneumonia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SF-36 score | — |
Countries
Japan
Outcome results
None listed